febuxostat has been researched along with Hyperglycemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T | 1 |
| Advani, A; Cherney, DZI; Fong, D; Har, R; Lai, V; Locke, A; Lytvyn, Y; Perkins, BA | 1 |
2 other study(ies) available for febuxostat and Hyperglycemia
| Article | Year |
|---|---|
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Febuxostat; Glucose Intolerance; Hyperglycemia; Hyperuricemia; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Kidney Glomerulus; Mice; Mice, Inbred C57BL; Mice, Obese; Oxidative Stress; Peptide Fragments; Uric Acid; Xanthine Oxidase | 2019 |
Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes.
Topics: Adult; Angiotensin II; Blood Pressure; Case-Control Studies; Diabetes Mellitus, Type 1; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperglycemia; Interleukin-18; Linear Models; Male; Nitric Oxide; Nitroglycerin; Renal Plasma Flow, Effective; Renin-Angiotensin System; Uric Acid; Vascular Stiffness; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Young Adult | 2017 |